Corcept Therapeutics Incorporated

Report azionario NasdaqCM:CORT

Capitalizzazione di mercato: US$12.8b

Corcept Therapeutics Crescita futura

Criteri Future verificati 5/6

Si prevede che Corcept Therapeutics aumenterà gli utili e i ricavi rispettivamente del 43% e 25.6% all'anno, mentre si prevede che l'EPS crescerà del 42.8% all'anno.

Informazioni chiave

43.0%

Tasso di crescita degli utili

42.79%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili18.8%
Tasso di crescita dei ricavi25.6%
Rendimento futuro del capitale proprion/a
Copertura analitica

Low

Ultimo aggiornamento18 Aug 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

Aggiornamento narrativa • Aug 06

CORT: Elevated Expectations Around Cushing’s Decision Will Shape Bearish Risk Outlook

Corcept Therapeutics' updated fair value estimate has moved from $88 to $50. This reflects analysts' wider range of views after several firms sharply raised their price targets into the $95 to $165 band, based on stronger recent results, expanded 2026 revenue guidance, and growing confidence in Lifyorli, Korlym, and the broader pipeline.
Articolo di analisi • Aug 05

We Think That There Are More Issues For Corcept Therapeutics (NASDAQ:CORT) Than Just Sluggish Earnings

Following the release of a lackluster earnings report from Corcept Therapeutics Incorporated ( NASDAQ:CORT ) the stock...
Aggiornamento narrativa • Jul 23

CORT: Regulatory Reset And New Indications Will Shape Balanced Risk Reward Outlook

For Corcept Therapeutics, the analyst-derived fair value estimate has been revised from $50 to $88, with analysts linking the higher target and increased assumed revenue growth to recent positive relacorilant regulatory updates and the potential for an additional indication. Analyst Commentary Recent research around Corcept Therapeutics highlights a mix of optimism around relacorilant and Lifyorli alongside pockets of caution, which matters if you are weighing how much execution or regulatory risk to price into the stock.
Seeking Alpha • Jul 10

Corcept Therapeutics: Recent Relacorilant Rejection Aside, A Good News Story For Investors

Summary Corcept Therapeutics maintains a Buy rating, supported by robust revenue growth, pipeline progress, and strong management execution. Relacorilant’s FDA approval in ovarian cancer and likely approval in Cushing’s syndrome could drive CORT revenues above $3 billion annually by decade’s end. 2026 revenue guidance of $950M–$1.05B reflects >30% YoY growth, with minimal impact expected from generic competition due to pipeline innovation. Despite a forward P/S of ~10x, CORT’s $10B+ market cap is justified by multi-billion dollar peak revenue potential and expanding clinical pipeline. Read the full article on Seeking Alpha
Aggiornamento narrativa • Jul 09

CORT: Regulatory Uncertainty Around Key NDA Resubmission Will Drive Future Downside Risk

Corcept Therapeutics' updated analyst price target of $50, down from $95, reflects analysts incorporating lower projected revenue growth, a slightly higher discount rate, and a more conservative future P/E multiple, even as they factor in improved profit margin assumptions and recent positive relacorilant and Lifyorli milestones. Analyst Commentary Recent Street research on Corcept Therapeutics has centered on the regulatory path for relacorilant, the commercial outlook for Lifyorli in ovarian cancer, and how these factors feed into valuation assumptions.
Aggiornamento narrativa • Jun 25

CORT: Ovarian Cancer Launch And Cushing’s Review Will Shape Balanced Outlook

Analysts have lifted their price targets on Corcept Therapeutics to a range of $72 to $135, citing the positive relacorilant NDA resubmission, the recent Lifyorli approval, and greater clarity on the regulatory path as key reasons for the higher valuation views. Analyst Commentary Recent research on Corcept Therapeutics points to a more constructive view on the stock, with several firms lifting price targets after the relacorilant NDA resubmission and the approval of Lifyorli.
Aggiornamento narrativa • Jun 06

CORT: Ovarian Cancer Data And Cushing’s Resubmission Will Drive Future Upside

Corcept Therapeutics' updated analyst price target has increased to $88.00 from $73.40, reflecting analysts' focus on recent price target revisions associated with the relacorilant NDA resubmission and the launch of Lifyorli in ovarian cancer. Analyst Commentary Recent Street research around Corcept Therapeutics centers on two main themes, the relacorilant regulatory path and the commercial opportunity for Lifyorli in ovarian cancer, with both feeding directly into updated valuation work.
Aggiornamento narrativa • May 11

CORT: New Ovarian Cancer Therapy Approval Will Support Future Upside

Analysts have raised Corcept Therapeutics' implied fair value target to $73.40 from $67.40. This reflects updated assumptions that indicate higher revenue growth and profit margins, slightly offset by a higher discount rate and a lower future P/E multiple following recent mixed price target revisions and a rating upgrade on the stock.
Aggiornamento narrativa • Apr 25

CORT: Ovarian Cancer Approval Will Support Future Upside Despite Patent Setback

Analysts have adjusted their price targets on Corcept Therapeutics, with changes such as H.C. Wainwright moving its target to $67, alongside offsetting increases from firms like Canaccord. These moves reflect updated views on patent risk, generic competition and the long term earnings profile implied by largely unchanged fair value, revenue growth, profit margin and future P/E assumptions.
Aggiornamento narrativa • Apr 11

CORT: Ovarian Cancer Approval Will Support Future Upside Despite Generic Headwinds

Corcept Therapeutics' updated analyst price target has been reset to $67, with analysts citing a tempered revenue growth outlook, slightly stronger expected profit margins, and an unchanged fair value and future P/E assumption. Analyst Commentary Recent Street research on Corcept Therapeutics reflects a mixed but engaged view, with several firms recalibrating price targets and ratings after legal and regulatory updates.
Aggiornamento narrativa • Mar 27

CORT: Ovarian Cancer Approval Will Drive Future Upside Despite Generic Risk

Corcept Therapeutics' updated analyst price target has moved to $67.40 from $65.40. Analysts cite refined fair value assumptions and a slightly higher future P/E multiple as they reassess the stock following mixed target changes across recent research coverage.
Aggiornamento narrativa • Mar 10

CORT: Future Generic Ruling And Oncology Data Will Drive Upside

Analysts have reduced their price target on Corcept Therapeutics to $67 from $105, reflecting lower fair value assumptions and revised expectations for revenue growth and profit margins after the court ruling that allows Teva's generic Korlym to participate in the Cushing's syndrome market. Analyst Commentary Recent research on Corcept Therapeutics clusters around the patent ruling on Teva's generic Korlym and its implications for the Cushing's syndrome market.
Aggiornamento narrativa • Feb 24

CORT: Future Court Ruling And Oncology Data Will Drive Long Term Upside

Analysts have reduced their fair value estimate for Corcept Therapeutics from $94.20 to $76.40 and the implied future P/E from 18.66x to 16.90x, reflecting a lower price target from $105 to $67 following the court decision allowing Teva's generic Korlym to compete, along with a more cautious view on revenue growth and profit margins. Analyst Commentary Recent research updates on Corcept Therapeutics focus heavily on the legal outcome around Teva's generic Korlym and what that could mean for valuation, growth expectations, and execution risk.
Aggiornamento narrativa • Feb 09

CORT: Future Regulatory And Oncology Outcomes Will Drive Long Term Upside

Analysts have raised their price target on Corcept Therapeutics by about $1, citing updated models that reflect steady assumptions for fair value, revenue growth, profit margins and future P/E. Recent research maintains the overall investment thesis despite regulatory developments.
Aggiornamento narrativa • Jan 26

CORT: Future Endocrine And Oncology Decisions Will Drive Long Term Upside

Narrative Update: Corcept Therapeutics Analysts have lifted their fair value estimate for Corcept Therapeutics to $94.20 from $91.00, citing updated assumptions around higher revenue growth, stronger profit margins, and a slightly lower future P/E multiple in their latest models. Analyst Commentary Recent research on Corcept Therapeutics has focused on how its Cushing's syndrome franchise could support long term growth, while also highlighting uncertainties around future positioning and execution.
Aggiornamento narrativa • Jan 10

CORT: Upcoming Endocrine And Oncology Decisions Will Shape Long Term Upside

Analysts have reset their price target framework for Corcept Therapeutics from about $127 to roughly $91, reflecting updated assumptions around revenue growth, profit margins, and a higher future P/E multiple, informed in part by recent coverage that compares relacorilant and Korlym with existing Cushing's syndrome treatments. Analyst Commentary Street research around Corcept Therapeutics is limited in the recent set of notes, but one new initiation helps frame how some investors might think about both the clinical and valuation setup for the stock.
Articolo di analisi • Jan 01

The Price Is Right For Corcept Therapeutics Incorporated (NASDAQ:CORT) Even After Diving 56%

Corcept Therapeutics Incorporated ( NASDAQ:CORT ) shareholders that were waiting for something to happen have been...
Aggiornamento narrativa • Dec 17

CORT: Upcoming Ovarian Cancer Decisions May Drive Upside Despite Pharmacy Transition Risks

Analysts have modestly trimmed their price target on Corcept Therapeutics to $127.20 from $134.50, reflecting a slightly higher discount rate. They also point to stronger long term revenue growth, expanding profit margins and a lower future P E multiple supported by continued confidence in the commercial potential of Korlym and relacorilant.
Articolo di analisi • Oct 07

Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 30% But Its P/E Still Looks Reasonable

The Corcept Therapeutics Incorporated ( NASDAQ:CORT ) share price has done very well over the last month, posting an...

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:CORT - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/20282,1828618888524
12/31/20271,7055945715324
12/31/20261,1462422982644
6/30/202683154107110N/A
3/31/202676947120120N/A
12/31/202576198142142N/A
9/30/2025741105163164N/A
6/30/2025716132181182N/A
3/31/2025685133177179N/A
12/31/2024675140196198N/A
9/30/2024629140142144N/A
6/30/2024570125123124N/A
3/31/2024524117125125N/A
12/31/2023482105127127N/A
9/30/202345091154155N/A
6/30/202342894135135N/A
3/31/202341494111111N/A
12/31/2022402101120120N/A
9/30/2022398117136136N/A
6/30/2022392113151151N/A
3/31/2022380112177178N/A
12/31/2021366113167168N/A
9/30/2021353106153154N/A
6/30/202134398134135N/A
3/31/202134099143144N/A
12/31/2020354106151152N/A
9/30/2020356109164165N/A
6/30/2020351114173173N/A
3/31/2020335106N/A146N/A
12/31/201930694N/A136N/A
9/30/201928587N/A109N/A
6/30/201926878N/A115N/A
3/31/201925876N/A105N/A
12/31/201825175N/A116N/A
9/30/2018238152N/A119N/A
6/30/2018216148N/A85N/A
3/31/2018189142N/A86N/A
12/31/2017159129N/A61N/A
9/30/201713035N/A41N/A
6/30/201710924N/A39N/A
3/31/20179313N/A25N/A
12/31/2016818N/A18N/A
9/30/2016725N/A18N/A
6/30/2016641N/A10N/A
3/31/201656-2N/A8N/A
12/31/201550-6N/A3N/A
9/30/201544-11N/A-2N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di CORT ( 43% all'anno) è superiore al tasso di risparmio ( 3.7% ).

Guadagni vs Mercato: Si prevede che gli utili di CORT ( 43% all'anno) cresceranno più rapidamente del mercato US ( 16.9% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di CORT cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di CORT ( 25.6% all'anno) crescerà più rapidamente del mercato US ( 12.9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di CORT ( 25.6% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di CORT è previsto essere elevato tra 3 anni

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/08/19 11:15
Prezzo dell'azione a fine giornata2026/08/19 00:00
Utili2026/06/30
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Corcept Therapeutics Incorporated è coperta da 19 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Tazeen AhmadBofA Global Research
Debjit ChattopadhyayBrean Capital Historical (Janney Montgomery)
David BuckB. Riley Securities, Inc.